Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12

Rhea-AI Summary

Aspira Women’s Health (AWH) will release its second quarter financial results for the period ending June 30, 2021, on August 12, 2021, after market close. An investor conference call will follow at 4:30 p.m. ET, where important updates and performance metrics will be discussed. Aspira is focused on women’s health, particularly in ovarian cancer risk assessment, offering FDA-cleared products like OVA1® and OVERA®. The company aims to develop innovative bio-analytical solutions to improve gynecologic health outcomes.

Positive

• Focus on ovarian cancer risk assessment and related products.
• FDA-cleared testing options OVA1® and OVERA® enhance market credibility.

Negative

• None.

AUSTIN, Texas, July 27, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the second quarter ended June 30, 2021 on Thursday, August 12, 2021, after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, August 12 at 4:30 pm ET
Domestic:	877-407-4018
International:	201-689-8471
Conference ID:	13720544
Webcast:	http://public.viavid.com/index.php?id=145272

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

FAQ

When will Aspira Women’s Health report its second quarter financial results?

Aspira Women’s Health will report its second quarter financial results on August 12, 2021, after market close.

What time is the investor conference call for Aspira Women’s Health?

The investor conference call for Aspira Women’s Health is scheduled for 4:30 p.m. ET on August 12, 2021.

What are the main products offered by Aspira Women’s Health?

Aspira Women’s Health offers OVA1® and OVERA®, FDA-cleared products for ovarian malignancy risk detection.

What is the focus of Aspira Women’s Health's testing solutions?

Aspira Women’s Health focuses on women's health, specifically ovarian cancer risk assessment and pelvic disease solutions.